Predicting response to radiotherapy: Evolutions and revolutions

References

• Adler A S, Lin M, Horlings H, Nuyten D S, Van De Vijver M J, Chang H Y. Genetic regulators of large-scale transcriptional signatures in cancer. Nature Genetics 2006; 38: 421–430
   PubMed Web of Science ®Google Scholar
• Alsner J, Andreassen C N, Overgaard J. Genetic markers for prediction of normal tissue toxicity after radiotherapy. Seminars in Radiation Oncology 2008; 18: 126–135
   PubMed Web of Science ®Google Scholar
• Amundson S A, Do K T, Vinikoor L C, Lee R A, Koch-Paiz C A, Ahn J, Reimers M, Chen Y, Scudiero D A, Weinstein J N, Trent J M, Bittner M L, Meltzer P S, Fornace A J, Jr. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Research 2008; 68: 415–424
   PubMed Web of Science ®Google Scholar
• Azria D, Ozsahin M, Kramar A, Peters S, Atencio D P, Crompton N E, Mornex F, Pelegrin A, Dubois J B, Mirimanoff R O, Rosenstein B S. Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clinical Cancer Research 2008; 14: 6284–6288
   PubMed Web of Science ®Google Scholar
• Barski A, Zhao K. Genomic location analysis by ChIP-Seq. Journal of Cell Biochemistry 2009; 107: 11–18
   PubMed Web of Science ®Google Scholar
• Begg A C, Haustermans K, Hart A A, Dische S, Saunders M, Zackrisson B, Gustaffson H, Coucke P, Paschoud N, Hoyer M, Overgaard J, Antognoni P, Richetti A, Bourhis J, Bartelink H, Horiot J C, Corvo R, Giaretti W, Awwad H, Shouman T, Jouffroy T, Maciorowski Z, Dobrowsky W, Struikmans H, Wilson G D. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: A multicenter analysis. Radiotherapy and Oncology 1999; 50: 13–23
   PubMed Web of Science ®Google Scholar
• Bjork-Eriksson T, West C, Karlsson E, Mercke C. Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. International Journal Radiation Oncology Biology Physics 2000; 46: 13–19
   PubMedGoogle Scholar
• Blasina A, Hallin J, Chen E, Arango M E, Kraynov E, Register J, Grant S, Ninkovic S, Chen P, Nichols T, O'Connor P, Anderes K. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Molecular Cancer Therapy 2008; 7: 2394–2404
   PubMed Web of Science ®Google Scholar
• Bourhis J, Overgaard J, Audry H, Ang K K, Saunders M, Bernier J, Horiot J C, Le Maitre A, Pajak T F, Poulsen M G, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay J H, Pinto L H, Fallai C, Fu K K, Sylvester R, Pignon J P. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. The Lancet 2006; 368: 843–854
   PubMed Web of Science ®Google Scholar
• Brandes A A, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. Journal of Clinical Oncology 2008; 26: 2192–2197
   PubMed Web of Science ®Google Scholar
• Brizel D M, Dodge R K, Clough R W, Dewhirst M W. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiotherapy and Oncology 1999; 53: 113–117
   PubMed Web of Science ®Google Scholar
• Brown D C, Gatter K C. Ki67 protein: The immaculate deception?. Histopathology 2002; 40: 2–11
   PubMed Web of Science ®Google Scholar
• Bryant H E, Schultz N, Thomas H D, Parker K M, Flower D, Lopez E, Kyle S, Meuth M, Curtin N J, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913–917
   PubMed Web of Science ®Google Scholar
• Burri R J, Stock R G, Cesaretti J A, Atencio D P, Peters S, Peters C A, Fan G, Stone N N, Ostrer H, Rosenstein B S. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiation Research 2008; 170: 49–59
   PubMed Web of Science ®Google Scholar
• Camps C, Buffa F M, Colella S, Moore J, Sotiriou C, Sheldon H, Harris A L, Gleadle J M, Ragoussis J. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Research 2008; 14: 1340–1348
   PubMed Web of Science ®Google Scholar
• Chan D A, Giaccia A J. Targeting cancer cells by synthetic lethality: Autophagy and VHL in cancer therapeutics. Cell Cycle 2008; 7: 2987–2990
   PubMed Web of Science ®Google Scholar
• Chi J T, Wang Z, Nuyten D S, Rodriguez E H, Schaner M E, Salim A, Wang Y, Kristensen G B, Helland A, Borresen-Dale A L, Giaccia A, Longaker M T, Hastie T, Yang G P, Van De Vijver M J, Brown P O. Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers. PLoS Medicine 2006; 3: e47
   PubMed Web of Science ®Google Scholar
• Chung C H, Parker J S, Ely K, Carter J, Yi Y, Murphy B A, Ang K K, El Naggar A K, Zanation A M, Cmelak A J, Levy S, Slebos R J, Yarbrough W G. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Research 2006; 66: 8210–8218
   PubMed Web of Science ®Google Scholar
• Conlin A K, Seidman A D. Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer. Molecular Diagnosis and Therapy 2007; 11: 355–360
   PubMedGoogle Scholar
• Dellapasqua S, Colleoni M, Gelber R D, Goldhirsch A. Adjuvant endocrine therapy for premenopausal women with early breast cancer. Journal of Clinical Oncology 2005; 23: 1736–1750
   PubMed Web of Science ®Google Scholar
• Dinh P, De Azambuja E, Cardoso F, Piccart-Gebhart M J. Facts and controversies in the use of trastuzumab in the adjuvant setting. Nature Clinical Practice Oncology 2008; 5: 645–654
   PubMedGoogle Scholar
• Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. The Lancet 1998; 351: 1451–1467
   PubMed Web of Science ®Google Scholar
• Eschrich S A, Pramana J, Zhang H, Zhao H, Boulware D, Lee J H, Bloom G, Rocha-Lima C, Kelley S, Calvin D P, Yeatman T J, Begg A C, Torres-Roca J F. A gene expression model of intrinsic tumor radiosensitivity: Prediction of response and prognosis after chemoradiation. International Journal of Radiation Oncology Biology and Physics 2009, in press
   Google Scholar
• Farmer H, Mccabe N, Lord C J, Tutt A N, Johnson D A, Richardson T B, Santarosa M, Dillon K J, Hickson I, Knights C, Martin N M, Jackson S P, Smith G C, Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917–921
   PubMed Web of Science ®Google Scholar
• Filipowicz W, Bhattacharyya S N, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight?. Nature Reviews Genetics 2008; 9: 102–114
   PubMed Web of Science ®Google Scholar
• Foekens J A, Sieuwerts A M, Smid M, Look M P, De Weerd V, Boersma A W, Klijn J G, Wiemer E A, Martens J W. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proceedings of the National Academy of Science of the USA 2008; 105: 13021–13026
   PubMed Web of Science ®Google Scholar
• Fu K K, Pajak T F, Trotti A, Jones C U, Spencer S A, Phillips T L, Garden A S, Ridge J A, Cooper J S, Ang K K. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. International Journal Radiation Oncology Biology Physics 2000; 48: 7–16
   PubMed Web of Science ®Google Scholar
• Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill R P. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. Journal of Clinical Oncology 2002; 20: 680–687
   PubMed Web of Science ®Google Scholar
• Giotopoulos G, Symonds R P, Foweraker K, Griffin M, Peat I, Osman A, Plumb M. The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. British Journal of Cancer 2007; 96: 1001–1007
   PubMed Web of Science ®Google Scholar
• Glas A M, Floore A, Delahaye L J, Witteveen A T, Pover R C, Bakx N, Lahti-Domenici J S, Bruinsma T J, Warmoes M O, Bernards R, Wessels L F, Van't Veer L J. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006; 7: 278–287
   PubMed Web of Science ®Google Scholar
• Hockel M, Knoop C, Schlenger K, Vorndran B, Knapstein P G, Vaupel P. Intratumoral pO2 histography as predictive assay in advanced cancer of the uterine cervix. Advances in Experimental Medicine and Biology 1994; 345: 445–450
   PubMedGoogle Scholar
• Idbaih A, Marie Y, Lucchesi C, Pierron G, Manie E, Raynal V, Mosseri V, Hoang-Xuan K, Kujas M, Brito I, Mokhtari K, Sanson M, Barillot E, Aurias A, Delattre J Y, Delattre O. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. International Journal of Cancer 2008; 122: 1778–1786
   PubMedGoogle Scholar
• Joosse S A, Van Beers E H, Tielen I H, Horlings H, Peterse J L, Hoogerbrugge N, Ligtenberg M J, Wessels L F, Axwijk P, Verhoef S, Hogervorst F B, Nederlof P M. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. Breast Cancer Research and Treatment 2009; 116: 479–489
   PubMed Web of Science ®Google Scholar
• Khodarev N N, Beckett M, Labay E, Darga T, Roizman B, Weichselbaum R R. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proceedings of the National Academy of Science of the USA 2004; 101: 1714–1719
   PubMed Web of Science ®Google Scholar
• Kim M Y, Yim S H, Kwon M S, Kim T M, Shin S H, Kang H M, Lee C, Chung Y J. Recurrent genomic alterations with impact on survival in colorectal cancer identified by genome-wide array comparative genomic hybridization. Gastroenterology 2006; 131: 1913–1924
   PubMedGoogle Scholar
• Mani S A, Guo W, Liao M J, Eaton E N, Ayyanan A, Zhou A Y, Brooks M, Reinhard F, Zhang C C, Shipitsin M, Campbell L L, Polyak K, Brisken C, Yang J, Weinberg R A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704–715
   PubMed Web of Science ®Google Scholar
• Marchionni L, Wilson R F, Wolff A C, Marinopoulos S, Parmigiani G, Bass E B, Goodman S N. Systematic review: Gene expression profiling assays in early-stage breast cancer. Annals of Internal Medicine 2008; 148: 358–369
   PubMed Web of Science ®Google Scholar
• Natrajan R, Little S E, Sodha N, Reis-Filho J S, Mackay A, Fenwick K, Ashworth A, Perlman E J, Dome J S, Grundy P E, Pritchard-Jones K, Jones C. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. Journal of Pathology 2007; 211: 52–59
   PubMed Web of Science ®Google Scholar
• Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiotherapy and Oncology 2000; 57: 39–43
   PubMed Web of Science ®Google Scholar
• Overgaard J, Hansen H S, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen J F. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. The Lancet 2003; 362: 933–940
   PubMed Web of Science ®Google Scholar
• Overgaard J, Hjelm-Hansen M, Johansen L V, Andersen A P. Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx. Acta Oncologica 1988; 27: 147–152
   PubMed Web of Science ®Google Scholar
• Ozsahin M, Crompton N E, Gourgou S, Kramar A, Li L, Shi Y, Sozzi W J, Zouhair A, Mirimanoff R O, Azria D. CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: A prospective study in 399 patients. Clinical Cancer Research 2005; 11: 7426–7433
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart M J, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios C H, Steger G, Huang C S, Huang C S, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter T M, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, Mcfadden E, Dolci M S, Gelber R D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine 2005; 353: 1659–1672
   PubMed Web of Science ®Google Scholar
• Pinkel D, Albertson D G. Comparative genomic hybridization. Annual Review of Genomics and Human Genetics 2005; 6: 331–354
   PubMed Web of Science ®Google Scholar
• Pramana J, Van Den Brekel M W, Van Velthuysen M L, Wessels L F, Nuyten D S, Hofland I, Atsma D, Pimentel N, Hoebers F J, Rasch C R, Begg A C. Gene expression profiling to predict outcome after chemoradiation in head and neck cancer. International Journal of Radiation Oncology Biology and Physics 2007; 69: 1544–1552
   PubMed Web of Science ®Google Scholar
• Quon H, Liu F F, Cummings B J. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head and Neck 2001; 23: 147–159
   PubMed Web of Science ®Google Scholar
• Rodningen O K, Borresen-Dale A L, Alsner J, Hastie T, Overgaard J. Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. Radiotherapy and Oncology 2008; 86: 314–320
   PubMed Web of Science ®Google Scholar
• Ross J S, Hatzis C, Symmans W F, Pusztai L, Hortobagyi G N. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008; 13: 477–493
   PubMed Web of Science ®Google Scholar
• Sarthy A V, Morgan-Lappe S E, Zakula D, Vernetti L, Schurdak M, Packer J C, Anderson M G, Shirasawa S, Sasazuki T, Fesik S W. Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Molecular Cancer Therapy 2007; 6: 269–276
   PubMed Web of Science ®Google Scholar
• Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Annals of Oncology 2008; 20: 175–1811
   PubMedGoogle Scholar
• Shedden K, Taylor J M, Enkemann S A, Tsao M S, Yeatman T J, Gerald W L, Eschrich S, Jurisica I, Giordano T J, Misek D E, Chang A C, Zhu C Q, Strumpf D, Hanash S, Shepherd F A, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan V E, Meyerson M, Kuick R, Dobbin K K, Lively T, Jacobson J W, Beer D G. Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nature Medicine 2008; 14: 822–827
   PubMed Web of Science ®Google Scholar
• Skladowski K, Maciejewski B, Golen M, Tarnawski R, Slosarek K, Suwinski R, Sygula M, Wygoda A. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: Long-term results of phase III clinical trial. International Journal of Radiation Oncology Biology and Physics 2006; 66: 706–713
   PubMedGoogle Scholar
• Sparano J A, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. Journal of Clinical Oncology 2008; 26: 721–728
   PubMed Web of Science ®Google Scholar
• Suga T, Iwakawa M, Tsuji H, Ishikawa H, Oda E, Noda S, Otsuka Y, Ishikawa A, Ishikawa K I, Shimazaki J, Mizoe J E, Tsujii H, Imai T. Influence of multiple genetic polymorphisms on genitourinary morbidity after carbon ion radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology and Physics 2008; 72: 808–813
   PubMedGoogle Scholar
• Svensson J P, Stalpers L J, Esveldt-Van Lange R E, Franken N A, Haveman J, Klein B, Turesson I, Vrieling H, Giphart-Gassler M. Analysis of gene expression using gene sets discriminates cancer patients with and without late radiation toxicity. PLoS Medicine 2006; 3: e422
   PubMed Web of Science ®Google Scholar
• Torres-Roca J F, Eschrich S, Zhao H, Bloom G, Sung J, Mccarthy S, Cantor A B, Scuto A, Li C, Zhang S, Jove R, Yeatman T. Prediction of radiation sensitivity using a gene expression classifier. Cancer Research 2005; 65: 7169–7176
   PubMed Web of Science ®Google Scholar
• Tu H F, Chen H W, Kao S Y, Lin S C, Liu C J, Chang K W. MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiotherapy and Oncology 2008; 87: 243–252
   PubMedGoogle Scholar
• Van Den Broek G B, Wreesmann V B, Van Den Brekel M W, Rasch C R, Balm A J, Rao P H. Genetic abnormalities associated with chemoradiation resistance of head and neck squamous cell carcinoma. Clinical Cancer Research 2007; 13: 4386–4391
   PubMedGoogle Scholar
• Vaupel P, Mayer A. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Reviews 2007; 26: 225–239
   PubMed Web of Science ®Google Scholar
• Vens C, Neijenhuis S, Verwijs-Janssen M, van den Broek L, Pourghiassian M, Begg A C. Base excision repair deficient cells rely on homologous recombination for survival after irradiation: A potential new strategy of tumor-specific radiosensitization. Radiotherapy and Oncology 2008; 88: S20
   PubMedGoogle Scholar
• Weber M, Hellmann I, Stadler M B, Ramos L, Paabo S, Rebhan M, Schubeler D. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nature Genetics 2007; 39: 457–466
   PubMed Web of Science ®Google Scholar
• West C M. Invited review: Intrinsic radiosensitivity as a predictor of patient response to radiotherapy. British Journal of Radiology 1995; 68: 827–837
   PubMed Web of Science ®Google Scholar
• Wojdacz T K, Hansen L L. Techniques used in studies of age-related DNA methylation changes. Annals of the New York Academy of Science 2006; 1067: 479–487
   PubMed Web of Science ®Google Scholar
• Wouters B G. Proteomics: Methodologies and applications in oncology. Seminars in Radiation Oncology 2008; 18: 115–125
   PubMed Web of Science ®Google Scholar
• Wu T, Sun W, Yuan S, Chen C H, Li K C. A method for analyzing censored survival phenotype with gene expression data. BMC Bioinformatics 2008; 9: 417
   PubMedGoogle Scholar
• Yu S L, Chen H Y, Chang G C, Chen C Y, Chen H W, Singh S, Cheng C L, Yu C J, Lee Y C, Chen H S, Su T J, Chiang C C, Li H N, Hong Q S, Su H Y, Chen C C, Chen W J, Liu C C, Chan W K, Chen W J, Li K C, Chen J J, Yang P C. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008; 13: 48–57
   PubMed Web of Science ®Google Scholar
• Zheng M, Morgan-Lappe S E, Yang J, Bockbrader K M, Pamarthy D, Thomas D, Fesik S W, Sun Y. Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Research 2008; 68: 7570–7578
   PubMedGoogle Scholar